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Abstract
Members of the APOBEC family of cellular cytidine deaminases represent a recently identified
group of proteins that provide immunity to infection by retroviruses and protect the cell from
endogenous mobile retroelements. Yet, HIV-1 is largely immune to the intrinsic antiviral effects of
APOBEC proteins because it encodes Vif (viral infectivity factor), an accessory protein that is
critical for in vivo replication of HIV-1. In the absence of Vif, APOBEC proteins are encapsidated by
budding virus particles and either cause extensive cytidine to uridine editing of negative sense
single-stranded DNA during reverse transcription or restrict virus replication through deaminase-
independent mechanisms. Thus, the primary function of Vif is to prevent encapsidation of APOBEC
proteins into viral particles. This is in part accomplished by the ability of Vif to induce the ubiquitin-
dependent degradation of some of the APOBEC proteins. However, Vif is also able to prevent
encapsidation of APOBEC3G and APOBEC3F through degradation-independent mechanism(s).
The goal of this review is to recapitulate current knowledge of the functional interaction of HIV-1
and its Vif protein with the APOBEC3 subfamily of proteins and to summarize our present
understanding of the mechanism of APOBEC3-dependent retrovirus restriction.
Background
HIV-1 Vif is a 23KD viral accessory protein that is required
for production of infectious virus in a cell type-specific
manner [1,2]. Viruses lacking a functional vif  gene are
severely restricted in their ability to replicate in non-per-
missive cell types when compared to wild type viruses.
Non-permissive cell types include primary T cells and
macrophages as well as some T cell lines (e.g. H9, CEM);
other cell lines (e.g. SupT1, Jurkat, CEM-SS) exhibit a "per-
missive" phenotype and allow the uninhibited replication
of vif-defective HIV-1 [3-8]. Results from heterokaryon
analyses, in which permissive and nonpermissive cell
lines had been fused, suggested that nonpermissive cells
expressed a host factor inhibiting the replication of vif-
defective HIV-1 [9,10]. Sheehy et al. subsequently identi-
fied this host factor through a subtractive cloning
approach as CEM15, now generally referred to as
APOBEC3G [11]. APOBEC3G is a cytidine deaminase
whose natural expression is largely restricted to nonper-
missive cells. Importantly, transfer of APOBEC3G into the
permissive CEMss cell line or transient expression of
APOBEC3G in 293T cells rendered these cells nonpermis-
sive, thus demonstrating the critical importance of
APOBEC3G in establishing a non-permissive phenotype
[11].
The APOBEC family of cytidine deaminases
APOBEC (apolipoprotein  BmRNA-editing  catalytic
polypeptide) proteins are a group of cytidine deaminases,
which in humans include AID and APOBEC1 (located on
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chromosome 12); APOBEC2 (chromosome 6); and a
series of seven APOBEC3 genes, which are tandemly
arrayed on human chromosome 22 [12]. These are
APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3DE,
APOBEC3F, APOBEC3G, and APOBEC3H (Fig. 1).
Recently, a new APOBEC subfamily, APOBEC4, was iden-
tified [13]. Human APOBEC4 is located on chromosome
1 and orthologs of APOBEC4 can be found in mammals,
chicken, and frogs. In mice, APOBEC4 seems to be prima-
rily expressed in testes but its function is currently
unknown [13]. In human tissues, APOBEC4 is only
poorly expressed and does not appear to restrict wild type
or vif-defective HIV-1 (Goila-Gaur, unpublished data).
APOBEC1 is an RNA editing enzyme and is the founding
member of the APOBEC family of cytidine deaminases
[14]; its expression in humans is restricted to the small
intestine where it is involved in the regulation of choles-
terol metabolism [15]. APOBEC1, in conjunction with
APOBEC complementing factor, acts in a highly specific
manner and normally deaminates only a single cytosine
(C6666) on the more than 14,000 nucleotide long apolipo-
protein B mRNA to create a premature translational stop
codon [14,16]. However, APOBEC1 editing fidelity was
found to be severely compromised when the protein was
overexpressed in rat hepatomas [17]. Similarly, overex-
pression of APOBEC1 in transgenic rabbits and mice led
to extensive non-specific editing of apoB mRNA as well as
other mRNAs and was associated with liver dysplasia and
hepatocellular carcinomas [18]. Finally, APOBEC1, when
overexpressed in Escherichia coli, even deaminates DNA
substrates [19] although the physiological significance of
DNA deamination by APOBEC1 remains unclear. These
results demonstrate that overexpression of APOBEC pro-
teins can lead to aberrant functional phenotypes that are
distinct from their normal physiological properties.
Structural characteristics of APOBEC proteins
All APOBEC family members contain a characteristic
domain structure. A short α-helical domain is followed by
a catalytic domain (CD), a short linker peptide, and a
pseudocatalytic domain (PCD) [12]. In APOBEC3B,
APOBEC3F and APOBEC3G, the entire unit is duplicated
to form the domain structure helix1-CD1-linker1-PCD1-
helix2-CD2-linker2-PCD2 [12]. Each catalytic domain
contains the conserved motif H-X-E-(X)27–28-P-C-X2–4-C
(Fig. 1), in which the His and Cys residues coordinate
Zn2+ and the Glu residue is involved in the proton shuttle
during the deamination reaction [12,20-22]. There is cur-
rently no high-resolution structure of APOBEC3G. This is
Human APOBEC proteins Figure 1
Human APOBEC proteins. Members of the APOBEC family contain either one or two CDA domains. Proteins are aligned 
based on their catalytically active deaminase domain (CDA) depicted in green. Catalytically inactive CDA domains in two-
domain enzymes are depicted in red. The consensus sequence for the CDA domains is shown at the bottom. Chromosomal 
association is shown on the left. Retrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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in part due to technical difficulties with the purification of
recombinant APOBEC3G, which is highly insoluble in
purified form and has a tendency to precipitate during
purification and concentration [23,24]. Despite these
technical difficulties one recent study provided initial
insights into the low resolution structure of APOBEC3G
using small angle x-ray scattering [25]. The authors pro-
posed an elongated structure for APOBEC3G that forms a
tail-to-tail dimer [25]. However, this structural model of
APOBEC3G is tentative and solving the high resolution
structure of APOBEC3G clearly is one of the most eminent
and challenging problems in the APOBEC field. An
important step towards this goal was accomplished by the
recent determination of the high resolution structure of
the C-terminal catalytic domain (CTD; residues 198–384)
of APOBEC3G [26]. It is important to keep in mind that
the authors had to introduce a number of amino acid
changes (L234K, F310K, C243A, C321A, and C356A) to
increase protein stability and solubility of the protein
although these changes did not affect deaminase activity
in an E. coli-based in vitro assay [26]. The APOBEC3G
CTD revealed a well-defined core structure of five alpha-
helices (α1 – α5) and five beta-strands (β1 – β5), in which
the zinc-coordinating catalytic domain encompasses heli-
ces α1 and α2 as well as the β3 strand [26].
APOBEC3G forms homo-multimers. The intrinsic pro-
pensity of APOBEC3G to multimerize was independently
verified in structural and biochemical studies [12,25,27-
32]. Indeed, fluorescent energy resonance transfer studies
suggest that the protein is packaged into viral particles as
an oligomer bound to RNA [32]. Interestingly, however,
multimerization does not appear to be obligatory for
APOBEC3G catalytic activity or virus encapsidation since
a dimerization-deficient mutant of APOBEC3G retained
both catalytic and antiviral activities [27]. Nevertheless,
wild type APOBEC3G does presumably assemble into oli-
gomeric structures under normal conditions and the ques-
tion concerning the correlation between oligomeric state
and biological function of APOBEC3G remains open. It is
also important to point out that the ability of APOBEC3G
to form homo-multimers is distinct from its ability to
assemble into large multi-protein complexes of high
molecular mass (HMM), which will be discussed below
(APOBEC3G complexes). This is exemplified by an
APOBEC3G mutant (APO C97A) incapable of homo-
multimerization that nevertheless retained its ability to
form large multi-protein complexes [33].
Unlike APOBEC1, which targets single-stranded RNA,
APOBEC3G selectively targets single-stranded DNA. The
enzyme does not deaminate double-stranded DNA or sin-
gle- or double-stranded RNA nor does it modify RNA/
DNA hybrids; however, APOBEC3G does bind all of these
substrates more or less efficiently [12,23,34-38].
APOBEC3G preferentially deaminates cytosine residues in
a CC dinucleotide context [34,35,39-43]. However, the
enzyme exhibits overall significantly lower substrate spe-
cificity than APOBEC1 and deaminates the HIV-1 genome
at multiple sites without apparent hot-spots. Neverthe-
less, there appears to be a gradient in APOBEC3G-induced
hypermutation of the HIV-1 genome that increases from
the 5' to the 3' end of the viral genome [34]. In fact, recent
studies identified twin gradients of APOBEC3G editing
with maxima mapping just 5' to a central polypurine tract
(cPPT) within the integrase gene on the HIV-1 genome
and 5' to the polypurine tract near the 3' LTR (3' PPT)
[44,45]. In addition, the region upstream of the primer
binding site near the 5'-end of the viral genome appeared
to be hypersensitive to APOBEC3G editing [44]. The
mechanistic basis of this phenomenon is not entirely
clear; however, the observed gradients were not due to a
possible polarizing effect of the PPT RNA:DNA heterodu-
plexes [44]. Instead, relative editing activity correlated
well with the time the minus strand DNA remains single
stranded [34,44]. An additional contributing factor to the
observed 5' to 3' gradient could be the processive manner,
in which APOBEC3G was shown to function [24].
In APOBECs carrying two deaminase domains (CD1 &
CD2), generally only one domain is catalytically active
while the second domain is involved in nucleic acid bind-
ing and virus encapsidation [23,27,29,46-49]. (Fig. 1).
One possible exception to this rule is APOBEC3B for
which one report found both deaminase domains to be
catalytically active [48]; however, this remains subject to
further investigation as another report did not detect cata-
lytic activity for the N-terminal deaminase domain in
APOBEC3B [50]. Interestingly, however, Hakata et al.
found that in murine APOBEC3, the N-terminal rather
than the C-terminal CD domain was important for cata-
lytic activity indicating that in the murine enzyme the cat-
alytically active and inactive domains are swapped [50].
APOBEC3G complexes
As noted above, APOBEC3G like most members of the
APOBEC family, can bind single-stranded RNA even
though its substrate is not RNA but single-stranded DNA
[23,34]. Indeed, the RNA binding property of APOBEC3G
may be important to regulate its catalytic and antiviral
activity. This is suggested by the finding that in vitro cata-
lytic activity of APOBEC3G is increased in RNase-treated
samples [51]. Also, APOBEC3A, which is packaged into
HIV-1 virions but lacks antiviral activity, acquires antiviral
activity when the N-terminal CD region of APOBEC3G is
inserted into the protein [52]. Furthermore, RNA may be
involved in regulating the formation of cytoplasmic
APOBEC3G high-molecular mass (HMM) ribonucleopro-
tein complexes [33,36,51,53,54]. Such HMM complexes
of APOBEC3G have been observed for endogenousRetrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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APOBEC3G in T cell lines and activated primary CD4+ T
lymphocytes as well as exogenously expressed
APOBEC3G in transfected HeLa or 293T cells. Immunocy-
tochemical analyses revealed a predominantly cytoplas-
mic localization for APOBEC3G. APOBEC3G – unlike
AID or APOBEC1 – is not a nucleocytoplasmic shuttle
protein. Indeed, work by Bennett et al. suggests that the
cytoplasmic localization of APOBEC3G is due to the pres-
ence of a cytoplasmic retention signal located in the N-ter-
minal region of the protein [55,56]. Interestingly,
APOBEC3G was also found in punctate cytoplasmic struc-
tures identified as mRNA processing bodies (P-bodies)
[36,57-59]. Furthermore, subjecting cells to stress induced
the rapid redistribution of APOBEC3G into stress granules
[59]. It is unclear if assembly of APOBEC3G into P bodies
or stress granules is a reversible process; however, these
structures are most likely part of the HMM component of
cellular APOBEC3G.
Activated CD4+ T lymphocytes are highly permissive to
infection by wild type HIV-1 in contrast to resting PBMC,
for which a post-entry restriction to HIV-infection was
observed [51]. Interestingly, there appears to be a correla-
tion between the intracellular configuration of
APOBEC3G and the cell's sensitivity to infection. In acti-
vated CD4+ T lymphocytes, APOBEC3G was predomi-
nantly found in a HMM ribonucleoprotein complex while
APOBEC3G in resting CD4+ T lymphocytes was primarily
in LMM configuration [51]. Analysis of APOBEC3G
deaminase activity in transiently transfected 293T cells
suggested that HMM APOBEC3G was less catalytically
active than LMM APOBEC3G; however, deaminase activ-
ity of HMM APOBEC3G could be restored by RNase-treat-
ment of the complexes [51]. Importantly, APOBEC3G
expression is upregulated by cytokine, tumor promoter, or
mitogen stimulation [60-65] and cytokine treatment of
cells induced a shift of LMM APOBEC3G to its HMM con-
formation paralleled by increased susceptibility to HIV-
infection. These observations have led to the proposal that
HMM APOBEC3G is catalytically inactive and has no anti-
viral activity while LMM APOBEC3G is capable of execut-
ing a post-entry block to HIV infection. It is important to
point out that the post-entry restriction of HIV-1 reported
by Chiu et al. [51] is a Vif-independent phenomenon and
is mechanistically distinct from the Vif-sensitive restric-
tion of HIV-1 in activated PBMC. Also, the post-entry
restriction in resting PBMC was not associated with DNA
editing [51]. Furthermore, it has been reported that HIV-1
is able to infect resting PBMC and that infection does not
require T cell activation [66,67]. Consistent with these
reports, APOBEC3G-imposed post-entry restriction was
not an absolute block to HIV-infection and viral DNA syn-
thesis was evident even in unstimulated PBMC albeit with
a 24 to 48 hr delay compared to activated cells [51]. Of
note, while the shift of APOBEC3G from LMM to HMM
conformation in activated PBMC may contribute to
increased HIV-1 replication, Vif-deficient HIV-1 remains
severely restricted in these cells. Unlike post-entry restric-
tion of resting PBMC, the Vif sensitive restriction of HIV-
1 in activated T cells depends on the encapsidation of
APOBEC3G into viral particles in the donor cell. Taking
into consideration that APOBEC3G is packaged from the
LMM pool of APOBEC3G [68] these results suggest that
even activated PBMC contain sufficient levels of LMM
APOBEC3G to severely limit replication of Vif-deficient
HIV-1. Thus, while the shift from LMM to HMM in acti-
vated PBMC abolishes post-entry restriction of HIV-1 in a
Vif-independent manner, vif-defective virus remains una-
ble to establish a spreading infection in activated T cells.
The ability to transition from LMM to HMM configuration
is not a peculiarity of APOBEC3G but has been observed
for APOBEC-1 and APOBEC3F as well [53,69,70]. Thus,
the ability of APOBEC to form high molecular mass ribo-
nucleoprotein complexes, while not necessarily relevant
to the cells' ability to control HIV-1, could be important
for the control of other intracellular events such as retro-
transposition by retroelements. In support of this,
APOBEC3G was found to inhibit retrotransposition of
Alu elements through sequestering Alu RNAs in cytoplas-
mic APOBEC3G ribonucleoprotein complexes [71,72].
On the other hand, APOBEC3A, which does not appear to
form high molecular mass multi-protein complexes, is a
potent inhibitor of LTR-retrotransposons and adeno-asso-
ciated virus [53,73-76] but does not generally inhibit ret-
roviruses with the exception of Rous sarcoma virus (RSV),
which is moderately sensitive to APOBEC3A [77].
Virus encapsidation of APOBEC3G
Among all APOBEC proteins, APOBEC3G has arguably
the strongest antiviral effect and most of the published
work concerning the antiviral activities of APOBEC pro-
teins involves APOBEC3G. APOBEC3G is incorporated
into budding HIV-1 virions in the absence of Vif, where it
mediates extensive dC to dU mutations of the minus-sin-
gle-stranded viral DNA formed during reverse transcrip-
tion. It has recently been shown that Vif-deficient virions
produced from human PBMC contain only about 7 (+/-
4) copies of APOBEC3G [78]; yet, these virions are com-
pletely non-infectious suggesting that the level of toler-
ance for virus-associated APOBEC3G is quite low. In
tissue culture assays packaging of APOBEC3G is roughly
proportional to the intracellular expression level and tran-
sient expression of APOBEC3G in HeLa cells can lead to
packaging of several hundred copies of APOBEC3G per
virion (Strebel, unpublished). Not surprisingly, muta-
tions introduced into HIV-1 genomes via deamination by
transiently over-expressed APOBEC3G can be quite exten-
sive and effectively block virus replication [34,39,41-
43,79-84]. While it is obvious how the introduction of GRetrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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to A mutations into a viral genome can have a negative
impact on viral fitness, a number of recent studies propose
additional deamination-independent activities of
APOBEC proteins, in particular APOBEC3G and
APOBEC3F [23,27,47,71,73-76,85-94]. However, the rel-
ative contribution of deamination-dependent and deami-
nation-independent activities of APOBEC3G and
APOBEC3F to their overall antiviral activity remains
unclear. Catalytically inactive APOBEC3F showed similar
antiviral potency than the wild type protein when ana-
lyzed in transiently transfected 293T cells [89]; catalyti-
cally inactive APOBEC3G, on the other hand, was
generally less effective than the wild type protein [27,89].
Importantly, when wild type or deaminase-defective
APOBEC3G was expressed in stable cell lines that were
selected to reflect close to physiological conditions,
mutant APOBEC3G exhibited no significant antiviral
activity, thus highlighting the importance of enzymatic
activity for APOBEC3G's antiviral effect [95,96]. It cannot
be ruled out, of course, that mutation of the APOBEC3G
catalytic domain induces conformational changes affect-
ing the protein's antiviral properties. Therefore, analyzing
the relative contribution of deaminase-dependent and -
independent activities to the overall antiviral effect of
APOBEC proteins will be a continuing effort.
Interestingly, the antiviral effects of APOBEC3G are not
limited to HIV-1 but extend to other retroviruses includ-
ing murine leukemia virus (MLV), mouse mammary
tumor virus (MMTV), simian immunodeficiency virus
(SIV), and equine infectious anemia virus (EIAV)
[39,42,79,97]. (Fig. 2). In addition, overexpression of
APOBEC3G was shown to block the replication of hepati-
tis B virus, a hepadnavirus whose life cycle includes the
reverse transcription of an RNA pregenome [88,98-106].
Packaging of APOBEC3G into such diverse viruses sug-
gests that virus encapsidation is either a relatively nonspe-
cific process or involves signals shared by these viruses. In
that respect it is of interest that even though APOBEC3G
targets single stranded DNA it nevertheless binds RNA
[12,23,34,37,38,107-109] and was found to interact with
the viral Gag precursor protein through its NC component
[42,79,107,110-113].  In vitro studies using purified
recombinant NC and APOBEC3G found that the two pro-
teins do not competitively bind RNA but instead form an
RNA-protein complex [23]. The nucleic acid binding
properties of APOBEC3G are associated with its two
deaminase domains. While the C-terminal deaminase
domain provides catalytic activity and thus engages sin-
gle-stranded DNA, the N-terminal deaminase domain is
catalytically inactive but may be important for RNA bind-
ing and encapsidation into virions [23,27,29,50,114]. The
interaction of the N-terminal deaminase domain with
RNA may also be a critical requirement for the encapsida-
tion of APOBEC3G into viral particles although this is still
an ongoing debate. Several studies suggested that viral
RNA or RNA in general is not a prerequisite for
APOBEC3G packaging; however, most of these reports
studied virus-like particles rather than whole virus [110-
112,115-117]. It is conceivable that the parameters gov-
erning encapsidation of APOBEC3G into virus-like parti-
cles differ from those for encapsidation into virions.
Arguments for the involvement of viral RNA come from
the observation that helper viruses and virus-like particles
lacking genomic RNA package about one third of the
APOBEC3G found in normal vif-deficient virions
[107,117]. Of note, when packageable viral RNA was pro-
vided in trans, APOBEC3G packaging was restored to wild
type efficiency [107]. Importantly, APOBEC3G packaged
into helper virus in the absence of viral RNA was not asso-
ciated with the viral core; however, addition of viral RNA
in trans restored core association of APOBEC3G [37,107].
These observations suggest that viral RNA enhances
encapsidation of APOBEC3G and promotes core-associa-
tion. A separate line of research has investigated the role
of cellular RNA and implicated 7SL RNA in the RNA-
mediated encapsidation of APOBEC3G [38]. 7SL RNA is
normally a component of signal recognition particles
(SRP); however, it is also an abundant component of HIV-
1 virions [37,38,118]. Interestingly, while the majority of
7SL RNA present in a cell is associated with SRP compo-
nents, only the 7SL RNA but not the SRP components
were identified in virion preparations. Indeed, overexpres-
sion of SRP19 reduced the packaging of 7SL RNA in a
dose-dependent manner but could be counteracted by
overexpression of exogenous 7SL RNA [38]. The absence
of SRP components from HIV-1 virions suggests a specific
packaging mechanism for 7SL RNA. Yet, the parameters
determining the packaging of 7SL RNA are still debated.
One group has identified the NC component of the viral
Gag precursor as the packaging determinant for 7SL RNA
[38,108]. while others did not observe a requirement for
NC in the packaging of 7SL RNA [37,118]. In the latter
case, minimal Gag constructs lacking NC were found to
package normal levels of 7SL RNA [118]. Also, helper
virus carrying a deletion of a putative packaging signal or
virus lacking functional NC zinc finger domains did not
package viral genomic RNA; such particles only incorpo-
rated background levels of APOBEC3G but packaged nor-
mal levels of 7SL RNA [37]. These data suggest that 7SL
RNA may be necessary but is not sufficient for the efficient
packaging of APOBEC3G.
Vif-induced proteasomal degradation of APOBEC3G
The antiviral activity of APOBEC3G is strongly inhibited
by Vif allowing the virus to replicate virtually unimpaired
in APOBEC3G-positive host cells. Other APOBECs are tar-
geted by Vif as well although there are significant differ-
ences in the relative sensitivity to Vif (Fig. 2). Also there is
a significant species-specificity that allows Vifs from someRetrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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Sensitivity of viruses or retroelements to inhibition by cytidine deaminases Figure 2
Sensitivity of viruses or retroelements to inhibition by cytidine deaminases. Viruses and retroelements are listed at 
the top and deaminases are listed on the left. Inhibition by deaminases was qualified as "no" (= insensitive to deaminase), weak 
(= weakly sensitive to deaminase), and "yes" (highly sensitive to deaminase). For HIV-1 and SIV viruses, the sensitivity to inhibi-
tion was further qualified as Vif-sensitive (red) and Vif-insensitive (blue). Sources of data are indicated in square brackets and 
include [11,31,39,42,43,73-76,79-81,84,86-88,98-106,126,143,144,175-187].Retrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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viruses to target APOBECs from certain host species but
not others (Fig. 2). Some of the Vif:APOBEC relationships
remain controversial; however, there is general agreement
that the inhibition of APOBEC3G's antiviral activity by Vif
is mediated through a physical interaction with
APOBEC3G that results in the exclusion of the deaminase
from virions. This effect of Vif is generally accompanied
by a reduction of the intracellular steady state levels. Over
time, expression of Vif can result in a striking depletion of
APOBEC3G in HIV-1-infected T cells while APOBEC3G
mRNA levels remain unaffected. APOBEC3G is an inher-
ently stable protein. In transiently transfected HeLa or
293T cells its half-life was calculated to > 8 hr and pulse/
chase analyses revealed that Vif reduced the half-life of
APOBEC3G to between 5 minutes and 4 hr depending on
the experimental setup [119-122]. This change in
APOBEC3G stability has been attributed to degradation
by the cellular ubiquitin-dependent proteasome machin-
ery [31,81,119-126]. The mechanism of APOBEC3G deg-
radation by Vif has been extensively studied and is now
relatively well understood (Fig. 3). Accordingly, degrada-
tion of APOBEC3G is triggered by a physical interaction
with Vif. Several domains in Vif critical for this effect have
now been identified (Fig. 3A). One of the domains
involved is a highly conserved motif near the C-terminus
of Vif, referred to as the SLQ motif. The SLQ(Y/F)LA
sequence resembles a conserved motif in the BC box of
the suppressors of cytokine signaling (SOCS) proteins and
was found to mediate binding of Vif to elongin C
[119,124,127,128]. a homolog to the yeast Skp1 protein
and a known component of E3 ubiquitin ligase com-
plexes. In addition, a highly conserved H-X5-C-X17–18C-
X3–5-H motif (also referred to as HCCH motif) located
upstream of the BC box was found to mediate interaction
with cullin-5 [127-129]. Furthermore, two cysteine resi-
dues that are part of the HCCH motif are critical compo-
nents of a zinc finger domain [130-133]. Zinc binding
appears to be important for Vif function since chelation of
zinc inhibited HIV Vif activity presumably by affecting the
proper folding of the protein [132,134]. The HCCH
domain together with the SLQ motif enable Vif to recruit
an ubiquitin ligase (E3) complex containing elongin C,
elongin B, cullin-5, and Rbx1 [124,127,128,130]. It is
believed that binding of Vif-Cullin-5/elonginB/elonginC/
Rbx1 complexes to APOBEC3G accelerates polyubiquit-
ylation of the deaminase and, as a result, targets
APOBEC3G for destruction by the 26S proteasome [120-
124,127,128]. (Fig. 3B). The ability of Vif to induce poly-
ubiquitylation of APOBEC3G was supported by in vitro
studies in which Vif coexpressed with cullin-5, elongin B,
elongin C, and Rbx1 assembled into a functional E3 ubiq-
uitin ligase complex and induced polyubiquitination of
immunopurified APOBEC3G in vitro [135]. These find-
ings are contrasted by a recent study demonstrating that
APOBEC3G lacking all lysine residues was nevertheless
sensitive to degradation by Vif [136]. The authors propose
that polyubiquitination of Vif may in that case provide the
signal necessary for targeting APOBEC3G to proteasomal
degradation. However, the precise mechanism of degrada-
tion of lysine-free APOBEC3G by Vif remains to be inves-
tigated.
Vif itself is a relatively unstable protein with a half-life of
~30 minutes and – like APOBEC3G – is degraded by cel-
lular proteasomes [137,138]. It is interesting that the turn-
over rates calculated for Vif and APOBEC3G do not match
[128](Strebel unpublished). Also, neither deletion of the
SLQ motif nor mutation of the HCCH motif in Vif, both
of which abolish APOBEC3G degradation, increased the
stability of Vif or prevented its polyubiquitination
(Strebel, unpublished) suggesting that Vif is not degraded
through the cullin-5 E3 ubiquitin ligase complex. Thus,
while there is solid evidence that Vif can induce polyubiq-
uitination and degradation of APOBEC3G by recruiting
the Cul5-E3 ubiquitin ligase complex, it seems unlikely
that Vif and APOBEC3G are co-degraded in this complex
and the mechanism of Vif degradation remains an open
question.
Degradation-independent Inhibition of APOBEC3G
Intracellular degradation of APOBEC3G clearly contrib-
utes to the exclusion of APOBEC3G from viruses. How-
ever, when a virus first infects a cell it faces high levels of
APOBEC3G and the amounts of Vif produced by the virus
are – at least initially – very low. Given that Vif affects
APOBEC3G steady-state levels in a dose-dependent man-
ner it can be assumed that the rate of APOBEC3G deple-
tion in newly infected cells is directly proportional to the
amounts of Vif expressed in these cells. Taking into
account the fact that kinetic studies determining the half-
lives of APOBEC3G were all done at relative excess of Vif
[119-122]., it is unlikely that progeny virus produced early
following infection is made in an APOBEC3G-free envi-
ronment. Thus, if the only function of Vif were to induce
degradation of APOBEC3G, virus produced early on
would likely be less infectious than virus produced later
on when intracellular levels of APOBEC3G have been
depleted by degradation. Such a phenomenon has, how-
ever, not been observed. In fact, there is increasing evi-
dence that Vif has additional functional properties that
prevent the encapsidation of APOBEC3G into virions in a
degradation-independent manner. The most striking
observation in that respect is the recent identification of a
degradation resistant form of APOBEC3G [33]. Degrada-
tion resistant APOBEC3G was still packaged into vif-defi-
cient HIV-1 virions and had antiviral properties.
Surprisingly however, Vif prevented the packaging of this
APOBEC3G variant and restored viral infectivity [33]. Fur-
thermore, the efficiency of Vif-induced APOBEC3G degra-
dation does not necessarily correlate with the efficiency ofRetrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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Model for Vif-induced degradation of APOBEC3G Figure 3
Model for Vif-induced degradation of APOBEC3G. (A) Sequence motifs in Vif implicated in the assembly of a Cul5-E3 
ubiquitin ligase complex. Two conserved domains in Vif, the HCCH motif and the SLQ motif are involved in binding Cul5 and 
elongin C (EloC). Vif coordinates one zinc molecule, which may be required to stabilize a structure important for the binding 
of cullin 5 (Cul5). (B) Adaptor model for Vif-induced APOBEC3G degradation. According to this model Vif is an adaptor mol-
ecule with binding sites for APOBEC3G and the Cul5-E3 ligase complex (1). Expression of Vif results in the formation of an 
APOBEC3G-Vif-E3 ternary complex (2). This triggers poly-ubiquitination of APOBEC3G (3) resulting in the degradation of 
APOBEC3G (4).Retrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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preventing APOBEC3G encapsidation suggesting that
these two effects can be functionally separated [126]. In
fact, in some cases Vif was able to prevent encapsidation
of APOBEC3G without apparent intracellular degradation
while at the other extreme, a fluorescently tagged Vif pro-
tein efficiently caused degradation of APOBEC3G but
failed to restore viral infectivity [126]. YFP-Vif alone did
not affect viral infectivity excluding the possibility that the
lack of infectivity in the latter example was caused by non-
specific toxicity of the tagged Vif [126]. Other, more subtle
observations also point to degradation-independent func-
tions of Vif. For instance, while encapsidation of
APOBEC3G into vif-deficient virions is generally propor-
tional to the intracellular expression level, reduction of
virus-associated APOBEC3G by Vif was in some cases sig-
nificantly more pronounced than the concomitant reduc-
tion of intracellular APOBEC3G levels [79,126,139,140].
Moreover, mutation of a serine residue at position 144 in
Vif (S144A) did not affect its ability to induce APOBEC3G
degradation yet severely impaired Vif's ability to govern
the production of infectious viruses from APOBEC3G-
expressing cells [128]. Finally, Vif was found to inhibit
enzymatic activity of APOBEC3G as well as the B-cell spe-
cific Activation-Induced Deaminase (AID) in a bacterial
assay system [141,142]. Interestingly, inhibition of
APOBEC3G and AID by Vif in the bacterial system was
sensitive to mutation of residue D128 in APOBEC3G or
the corresponding D118 in AID, which in other experi-
ments was shown to affect physical interaction of Vif and
APOBEC3G [143-146]. Since E. coli lacks a proteasomal
degradation machinery, these results suggest that Vif can
affect the enzymatic activity of APOBEC3G in the absence
of proteasomal degradation. It is unclear, how Vif inhibits
encapsidation of degradation resistant APOBEC3G or
how it inhibits the in vitro deaminase activity of the
enzyme in the E. coli assay. Inhibition of deaminase activ-
ity by steric interference cannot be ruled out; however, a
non-functional Vif variant carrying a mutation in the
HCCH box required for assembly of the Cul5 E3 ligase
complex was still capable of interacting with APOBEC3G
in vitro yet did not inhibit deaminase activity [141,142].
Two other possible mechanisms can therefore be envi-
sioned: (i) Vif prevents packaging of APOBEC3G through
competitive binding to a common packaging signal; sup-
port for this model comes from the observation that the
parameters for encapsidation of APOBEC3G and Vif into
HIV-1 virions are very similar (Strebel and Khan, unpub-
lished); (ii) Vif promotes or accelerates the transition of
APOBEC3G from LMM to HMM conformation. Support
for the second model comes from the recent observation
that Vif can induce conformational changes in
APOBEC3G and promote the assembly of APOBEC3G
into HMM complexes in vitro and in vivo [54]. It is also
possible that both mechanisms co-exist; however, mecha-
nistic details of the degradation-independent exclusion of
APOBEC3G from HIV-1 virions have yet to be worked
out. In summary, current data suggest that Vif has func-
tional properties that can prevent the packaging of
APOBEC3G and inhibit its catalytic activity through deg-
radation-dependent as well as degradation-independent
mechanisms.
Vif/APOBEC interactions
The ability of Vif to block the antiviral activity of
APOBEC3G is species-specific [79,147,148]. The Vif pro-
teins of HIV-1 and SIVAgm can inhibit APOBEC3G of their
natural hosts but are not known to target APOBEC3G of
other species. Accordingly, HIV-1 Vif is unable to neutral-
ize the antiviral activity of African green monkey (Agm) or
rhesus APOBEC3G. Conversely, SIVAgm Vif is unable to
neutralize human or macaque APOBEC3G. Thus, the Vif
proteins of HIV-1 and SIVAgm function in a highly species-
specific manner. The Vif protein of SIVMac on the other
hand acts more broadly and is able to neutralize
APOBEC3G proteins from humans, African green mon-
keys, and rhesus macaques [79]. Several independent
studies found that a single amino acid residue at position
128 in human APOBEC3G was responsible for the species
specificity and change of this residue from the human to
the Agm sequence (D128K) was sufficient to reverse sen-
sitivity to HIV-1 and SIVAgm Vif [143-146]. Most studies
found that mutation at position 128 severely affected the
binding of APOBEC3G to Vif [143-145]. As far as Vif is
concerned it was observed that amino acid changes near
the N-terminus (residues 14–17) affected the species-spe-
cific interaction with APOBEC3G [149,150]. In addition,
mutation of residues 40 to 44 in HIV-1 Vif were found to
affect interaction with APOBEC3G [150,151]. and dele-
tion of residues 43–59 abolished APOBEC3G interaction
[57]. In fact, deletions in multiple regions of Vif can lead
to a loss of interaction with APOBEC3G [121]. Interest-
ingly, our own studies show that deletion of residues 23–
43 in Vif had no effect on APOBEC3G interaction. The fact
that in some cases amino acid changes in Vif appeared to
have a more pronounced effect on APOBEC3G interac-
tions than deletion of the same region suggest conforma-
tional constraints. Thus, residues 40–44 may be critical for
proper folding of Vif but are unlikely to constitute the
entire APOBEC3G binding site. Consistent with this,
interference studies using overlapping Vif peptides dem-
onstrate that residues 33 to 88 in Vif are important to
form a non-linear binding site for APOBEC3G [151].
These results are supported by our own data showing
severe loss of interaction with APOBEC3G for Vif mutants
carrying deletions of residues 38 to 69 and 77 to 125,
respectively (Strebel, unpublished). Finally, Vif was
reported to form oligomeric structures. Dimerization was
shown to involve residues 156 to 164 near the C-terminus
of Vif and was found to be important for its biological
activity [152,153]. Indeed, a peptide antagonist to VifRetrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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dimerization increased encapsidation of APOBEC3G into
Vif+ HIV-1 virions suggesting that Vif oligomerization is
important for interaction with APOBEC3G [153].
Mechanism of APOBEC-mediated inhibition of viral 
infectivity
While catalytic activity of APOBEC3G undoubtedly is
important for its antiviral effect, the precise mechanism
that leads to inhibition of viral infectivity remains
unclear. Hypermutation of viral genomes clearly is detri-
mental to HIV-1 spreading infections as mutations in the
viral structural and non-structural proteins can lead to
replication defects at multiple levels. However, there is
still an ongoing discussion on whether editing of the viral
genome can explain all the phenomena associated with
infection by APOBEC-containing vif-defective HIV.
One possible alternative/additional mechanism to the
accumulation of debilitating mutations in the viral
genome is the degradation of uracilated viral cDNA
through the activity of cellular DNA glycosylases, e.g.
UNG and SMUG1. Degradation of nascent viral cDNAs
would explain the efficient inhibition of HIV-1 in single
round infectivity assays, which often only require de novo
synthesis of HIV-1 Tat, an inefficient target for
APOBEC3G due to its size, base composition, and loca-
tion in the viral genome. Mutations in structural genes
(i.e. gag, pol, or env) would not affect the readout of a sin-
gle cycle assay because such mutations would only gain
weight during progeny virus production in multi-round
replication assays. Thus, the impact of editing on
APOBEC3G-imposed restriction of HIV-1 in vivo may be
underestimated by single-cycle infectivity assays. Never-
theless, degradation of nascent viral cDNAs would explain
early observations on the role of Vif for the production of
full-length viral reverse transcripts [7,154-156]. However,
the functional interplay of APOBEC and DNA glycosy-
lases is far from clear. One previous report found that the
nuclear form of UNG (UNG2) is packaged into HIV-1 vir-
ions through an interaction with Vpr to modulate the viral
mutation rate independent of APOBEC3G [157]. Another
study concluded that Vpr, in fact, reduces the packaging of
UNG and SMUG into HIV-1 virions by inducing their pro-
teasomal degradation [158]. A third study did not observe
any effect of Vpr on UNG packaging [159]. Consistent
with this study, a fourth study reported that UNG packag-
ing was, indeed, Vpr independent and instead involved an
interaction with the HIV-1 integrase [160]. Thus, the
mode of UNG packaging remains under discussion; how-
ever, most studies agree on the presence of UNG2 in HIV-
1 virions. Nevertheless, the role of UNG in APOBEC3G
mediated restriction of HIV-1 remains unclear. Kaiser et al
found that the presence or absence of active UNG in
donor or target cells had no impact on the antiviral activ-
ity of APOBEC3G [159]. Also, UNG2 appeared to be
absent from highly purified HIV-2 or SIVmac239 virions
[161] suggesting that, if at all, UNG2 would function in a
virus-specific manner. Furthermore, overexpression of the
UNG inhibitor Ugi in virus producing cells did not impair
APOBEC3G function [82,159]. Finally, experiments in
chicken fibroblasts lacking SMUG1 activity did not reveal
an effect of UNG or SMUG1 on APOBEC3G mediated
restriction of HIV-1 or Rous Sarcoma virus [162]. These
observation are contrasted by studies reporting that (i)
Vpr-mediated incorporation of UNG2 into HIV-1 parti-
cles is required to modulate the virus mutation rate and
for replication in macrophages [163] and (ii) that virion-
associated UNG-2 and apurinic/apyrimidinic endonucle-
ase are involved in the degradation of APOBEC3G-edited
nascent HIV-1 DNA [164].
When considering these seemingly contradictory reports,
one must keep in mind that most of these studies involved
transiently transfected APOBEC3G. Transient expression
of APOBEC3G can lead to deaminase-dependent and
deaminase-independent antiviral activity [89,95]. This
raises the possibility that some of the seemingly conflict-
ing results on the role of UNG or SMUG are due to deam-
inase-independent effects of APOBEC3G. Deaminase-
independent effects of APOBEC3G on HIV-1 could poten-
tially mask deaminase-dependent effects involving UNG1
or SMUG1, especially if APOBEC3G is expressed at high
levels (see chapter on deaminase independent activities of
APOBEC3G below). Also, mammalian cells contain at
least two additional glycosylases, TDG and MBD4, capa-
ble of removing uracil from DNA (reviewed in [165]).
UNG and SMUG1 are capable of targeting uracil in single-
and double-stranded DNA while TDG and MBD4 glycosy-
lases selectively target double-stranded DNA [166]. Given
those substrate specificities it is unlikely that TDG or
MBD4 are involved in APOBEC3G-dependent degrada-
tion of uridylated viral DNA. However, it cannot be ruled
out that mammalian cells contain other yet unidentified
DNA repair mechanisms with single-stranded DNA spe-
cificity.
Deaminase independent activities of APOBEC3G
Previous reports of APOBEC3G-induced hypermutation
have correlated cytidine deaminase activity with antiviral
function [30,42,43]. There have been multiple recent
reports indicating that the antiviral activity of APOBEC3G
can be dissociated from its cytidine deaminase activity
[47,85,89]. The deamination-independent inhibition of
viral replication appears to be multifaceted and there is no
clear consensus yet on this topic. For instance, one group
reported that APOBEC3G and APOBEC3F inhibit the
annealing of tRNA(3)(Lys) to viral RNA thereby interfer-
ing with tRNA-primed initiation of reverse transcription
[91-93] while another group did not observe an effect of
APOBEC3G on tRNA primer annealing but instead foundRetrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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that the protein significantly inhibited all RT-catalyzed
DNA elongation reactions [90]. APOBEC3G also was
implicated in the inhibition of strand transfer reactions
[82,94]. and APOBEC3G and APOBEC3F were found to
inhibit DNA synthesis and integration [83]. All of these
effects of APOBEC3G and APOBEC3F were deamination
independent and were observed for the most part with
transiently transfected APOBEC3G or purified recom-
binant protein. Again, the field is not unified as one report
found that catalytically inactive APOBEC3G inhibited
viral DNA synthesis and integration significantly less effi-
ciently than wild type APOBEC3G [82]. Similar to these
donor cell specific effects, the reported post-entry restric-
tion of HIV-1 in resting PBMC also did not appear to
involve hypermutation of de novo synthesized viral DNA
and thus may have been deaminase independent [51].
Finally, some of the antiviral effects of APOBEC proteins
towards HTLV-1 and Hepatitis B virus did not require
deaminase activity [99,104,167,168]. Nevertheless, other
reports did identify APOBEC-induced hypermutations in
Hepatitis B genomes using sensitive detection methods
[98,100,105,169]. Again, most of these studies involved
cells expressing experimentally increased levels of
APOBEC3G and the importance of APOBEC proteins for
the control of HTLV and Hepatitis B in vivo at physiologi-
cal APOBEC levels remains to be evaluated.
APOBEC family of proteins as therapeutics
APOBEC proteins and in particular APOBEC3G can pro-
vide potent intrinsic immunity to infection by viruses
whose life cycle involves a single-stranded DNA step.
Unfortunately, some viruses including HIV have evolved
countermeasures to bypass the APOBEC3G mediated
immunity. In the case of HIV-1, the viral accessory protein
Vif inhibits the encapsidation of APOBEC3G and thus
enables the virus to escape its antiviral effect. Inhibition of
APOBEC3G encapsidation by Vif, whether it happens
through proteasomal degradation or via a degradation-
independent mechanism, requires the physical interac-
tion of Vif and APOBEC3G. Thus, disrupting the Vif/
APOBEC3G interaction by small molecule inhibitors or
through pharmacological approaches has tremendous
potential for antiviral therapy and is an active area of
research. Nevertheless, there has been concern that target-
ing APOBEC3G could have the opposite effect and, in fact,
favor the virus under conditions where APOBEC3G activ-
ity is only partially inhibited. It was argued that while a
highly effective Vif inhibitor may result in mutational
meltdown of the viral quasispecies, a partially effective Vif
inhibitor may accelerate the evolution of drug resistance
and immune escape due to the codon structure and
recombinogenic nature of HIV-1 [170]. This view is sup-
ported by a recent report studying the effects APOBEC3G
on viral isolates containing partially defective Vif alleles.
The authors identified spontaneous drug resistance in
viruses that had recombined with presumably defective
hypermutated viral genomes [171]. Thus, suboptimal Vif
function or partial inhibition of the Vif/APOBEC3G inter-
action through pharmacological methods can indeed
result in the evolution of an HIV-1 quasispecies capable of
rapidly adapting to environmental challenges. Neverthe-
less, it is important to keep in mind that the drug resist-
ance variants that arose in the study by Mulder et al came
from superinfection by wild type virus and resistant
viruses invariably contained wild type Vif alleles. This
could suggest that HIV-1 cannot survive long-term with
partially active Vif or with partially inhibited Vif/
APOBEC3G interactions. Thus, there is reason to be opti-
mistic about the potential efficacy and safety of drugs tar-
geting APOBEC3G.
Another approach to bypass the effects of Vif is to elimi-
nate the Vif-sensitive N-terminal domain of APOBEC3G
and target APOBEC into HIV-1 cores as a fusion to Vpr.
This approach was successfully applied by Aguiar et al.
who fused APOBEC3A to Vpr and found that the chimera
was efficiently packaged into cores of HIV-1 and SIV viri-
ons and potently inhibited viral replication in a Vif-inde-
pendent manner [172]. Aside from inhibiting the Vif/
APOBEC interaction or bypassing Vif function by remov-
ing Vif-sensitive domains, decreasing the Vif:APOBEC
ratio by boosting cellular expression of APOBEC3G could
offer another way to outmaneuver HIV-1. APOBEC3G
expression can be upregulated several fold by interferon
treatment in human PBMC, primary human brain micro-
vascular endothelial cells, and primary macrophages
[60,64,173]. In addition, APOBEC3A expression is highly
responsive to interferon treatment of human monocytes
and monocyte-derived macrophages and APOBEC3A
expression was inversely correlated with susceptibility to
HIV infection [174]. Similarly, interferon-alpha treatment
of human hepatocytes resulted in increased expression of
APOBEC3G [101,102]. However, a subsequent study con-
cluded that the induction of antiviral cytidine deaminases
did not explain the inhibition of hepatitis B virus replica-
tion by interferons [106]. Thus, much work remains to be
done before we fully understand the intricate details of
APOBEC regulation and antiviral activities.
Concluding Remarks
Since the identification of APOBEC3G as the primary tar-
get of Vif activity, research on cytidine deaminases has
exploded and APOBEC proteins are arguably among the
best studied cellular enzymes. We now know that
APOBEC proteins are central to an intrinsic host defense
mechanism that has evolved over millions of years. Thus,
Vif/APOBEC3G interactions provide an important new
target for antiviral therapy. Much progress has been made;
however, there is a long way to go before we can claim to
fully understand the complex interactions of HIV withRetrovirology 2008, 5:51 http://www.retrovirology.com/content/5/1/51
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APOBEC proteins. Obtaining a high-resolution structure
of APOBEC3G and Vif for instance will be crucial to intel-
ligent drug design. There are promising signs that the tech-
nical problems that have hampered progress until now in
the structural area can be overcome in the near future.
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